A phase 1, open label, dose-escalation, pharmacodynamic study of intranodal injection of adenovirus-CD154 (Ad-ISF350) in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma

Trial Profile

A phase 1, open label, dose-escalation, pharmacodynamic study of intranodal injection of adenovirus-CD154 (Ad-ISF350) in patients with chronic lymphocytic leukemia / small lymphocytic lymphoma

Completed
Phase of Trial: Phase I

Latest Information Update: 20 Jul 2010

At a glance

  • Drugs CD154 gene therapy (Primary)
  • Indications Chronic lymphocytic leukaemia
  • Focus Adverse reactions
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 10 Jun 2010 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 10 Jun 2010 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top